CELLADON, TARGETED GENETICS COLLABORATE TO DEVELOP AAV-BASED GENE THERAPIES FOR CONGESTIVE HEART FAILURE

Targeted Genetics and Celladon have announced a collaboration agreement to develop adeno associated virus (AAV)-based gene therapies for the treatment of congestive heart failure (CHF).

Simultaneous with the initiation of this collaboration, Enterprise Partners and Venrock Associates, venture capital funds that have invested in Celladon, made a $6 million common stock investment in Targeted Genetics.

The collaboration combines Targeted Genetics' expertise in the development, manufacture and clinical evaluation of AAV-based therapies with Celladon's portfolio of genes with potential in the treatment of CHF. Under the terms of the agreement, Targeted Genetics and Celladon will work together to develop AAV vectors for the treatment of heart failure.